• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

依前列醇对系统性硬化症合并肺动脉高压患者的血流动力学影响。

Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.

作者信息

Strange C, Bolster M, Mazur J, Taylor M, Gossage J R, Silver R

机构信息

Division of Pulmonary and Critical Care Medicine, Allergy and Clinical Immunology, Medical University of South Carolina, Charleston, USA.

出版信息

Chest. 2000 Oct;118(4):1077-82. doi: 10.1378/chest.118.4.1077.

DOI:10.1378/chest.118.4.1077
PMID:11035680
Abstract

STUDY OBJECTIVES

To determine the cause of pulmonary hypertension (PH) in systemic sclerosis (SSc) patients since PH can occur because of pulmonary arteriopathy, pulmonary parenchymal destruction, and left ventricular cardiac dysfunction.

DESIGN AND SETTING

Consecutive case series in a university hospital.

PATIENTS

Nine SSc patients with PH (mean pulmonary artery pressure, 41 mm Hg), with (n = 6) or without (n = 3) concomitant interstitial lung disease (ILD).

METHODS

Acute infusion of epoprostenol was begun at 2 ng/kg/min and was titrated upward at a rate of 2 ng/kg/min every 30 min until symptomatic complications developed or pulmonary artery vascular resistance (PVR) was reduced by 50%.

RESULTS

Eight of nine patients demonstrated a reduction of > or = 20% in PVR, suggesting that vasoreactivity is common despite the presence of significant ILD. A single patient had no response to infusion with unchanged hemodynamics and oxygenation. One patient developed hypoxemia as cardiac output increased, suggesting a worsening of ventilation/perfusion matching or the presence of an anatomic shunt. Acute pulmonary edema developed in one patient at an infusion rate of 6 ng/kg/min. The results of cardiac catheterization suggested that pulmonary edema was caused by SSc heart disease.

CONCLUSION

SSc patients with ILD have diverse and sometimes multiple causes of PH that can be determined by short-term epoprostenol infusion. Beneficial effects can be obtained from epoprostenol despite extensive ILD.

摘要

研究目的

确定系统性硬化症(SSc)患者肺动脉高压(PH)的病因,因为PH可能由肺动脉病变、肺实质破坏和左心室心功能不全引起。

设计与地点

大学医院的连续病例系列研究。

患者

9例患有PH的SSc患者(平均肺动脉压为41mmHg),其中6例伴有间质性肺疾病(ILD),3例不伴有ILD。

方法

开始以2 ng/kg/min的速度急性输注依前列醇,每30分钟以2 ng/kg/min的速度递增,直至出现症状性并发症或肺动脉血管阻力(PVR)降低50%。

结果

9例患者中有8例PVR降低≥20%,这表明尽管存在严重的ILD,血管反应性仍很常见。1例患者对输注无反应,血流动力学和氧合情况未改变。1例患者在心输出量增加时出现低氧血症,提示通气/灌注匹配恶化或存在解剖分流。1例患者在输注速度为6 ng/kg/min时发生急性肺水肿。心导管检查结果提示肺水肿由SSc心脏病引起。

结论

患有ILD的SSc患者的PH病因多样,有时是多种原因,可通过短期输注依前列醇来确定。尽管存在广泛的ILD,但依前列醇仍可产生有益效果。

相似文献

1
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.依前列醇对系统性硬化症合并肺动脉高压患者的血流动力学影响。
Chest. 2000 Oct;118(4):1077-82. doi: 10.1378/chest.118.4.1077.
2
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.特发性肺纤维化相关肺动脉高压与系统性硬化症相关肺动脉高压患者治疗后血流动力学反应及结局比较:特发性肺纤维化相关肺动脉高压预后因素研究数据。
Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29.
3
Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.持续静脉输注依前列醇治疗硬皮病谱系疾病所致肺动脉高压:一项随机对照试验。
Ann Intern Med. 2000 Mar 21;132(6):425-34. doi: 10.7326/0003-4819-132-6-200003210-00002.
4
Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).系统性硬化症相关肺动脉高压:依前列醇(前列环素)的短期和长期影响
Arthritis Rheum. 1999 Dec;42(12):2638-45. doi: 10.1002/1529-0131(199912)42:12<2638::AID-ANR20>3.0.CO;2-X.
5
Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.连续静脉输注前列环素成功用于一名重度门肺高压患者。
Wien Klin Wochenschr. 2000 Jul 28;112(14):637-40.
6
The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis.前列环素对系统性硬化症继发肺动脉高压患者肺血流动力学的急性影响。
Arthritis Rheum. 1998 Mar;41(3):466-9. doi: 10.1002/1529-0131(199803)41:3<466::AID-ART13>3.0.CO;2-O.
7
Acute effects of nebulised epoprostenol in pulmonary hypertension due to systemic sclerosis.雾化吸入依前列醇对系统性硬化症所致肺动脉高压的急性影响。
Respir Med. 1999 Feb;93(2):75-8. doi: 10.1016/s0954-6111(99)90294-9.
8
[Impact of bosentan therapy on stress-induced pulmonary hypertension in patients with systemic sclerosis].波生坦治疗对系统性硬化症患者应激性肺动脉高压的影响
Ter Arkh. 2015;87(1):49-56. doi: 10.17116/terarkh201587149-56.
9
Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study.系统性硬皮病患者运动诱导性肺动脉高压的临床和超声心动图相关性:一项多中心研究。
Am Heart J. 2013 Feb;165(2):200-7. doi: 10.1016/j.ahj.2012.10.020. Epub 2012 Nov 28.
10
Defective endothelially mediated pulmonary vasodilation in systemic sclerosis.系统性硬化症中内皮介导的肺血管舒张功能缺陷。
Chest. 1998 Jul;114(1):178-84. doi: 10.1378/chest.114.1.178.

引用本文的文献

1
Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment.结缔组织疾病相关肺动脉高压:病理生理学与治疗。
Exp Biol Med (Maywood). 2019 Feb;244(2):120-131. doi: 10.1177/1535370218824101. Epub 2019 Jan 22.
2
Right heart catheterization procedures in patients with suspicion of pulmonary hypertension - experiences of a tertiary center.疑似肺动脉高压患者的右心导管检查程序——三级中心的经验
Postepy Kardiol Interwencyjnej. 2017;13(4):295-301. doi: 10.5114/aic.2017.71610. Epub 2017 Nov 29.
3
Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension.
吸入一氧化氮联合氧气时的血管反应性可预测肺动脉高压患者的长期生存率。
Pulm Circ. 2011 Apr;1(2):250-258. doi: 10.4103/2045-8932.83449.
4
How should we treat vascular and fibrotic lung disease in scleroderma?我们应该如何治疗硬皮病中的血管性和纤维化性肺病?
F1000 Med Rep. 2009 Jul 27;1:57. doi: 10.3410/M1-57.
5
Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study.
Curr Rheumatol Rep. 2005 Apr;7(2):135-41. doi: 10.1007/s11926-005-0066-z.